Event Date/Time: May 03, 2004
End Date/Time: May 05, 2004
IBC’s Targeting Metabolic Syndrome brings together industry and academic researchers working to reveal new targets for these diseases. Discussion will focus on the development of therapeutic prospects for controlling the set of early risk factors that can develop into Metabolic Syndrome. Updates from our marquis faculty will include the phenomena of Metabolic Syndrome and the potential for single therapeutic agents; clinical studies of high HDL cholesterol and its relationship to Metabolic Syndrome; new PPAR agonists and their impact on animal models of T2D and obesity; potential indications in metabolic diseases of the anticonvulsants Topiramate and Zonisamide; and new animal models for discovery and validation of novel therapeutic targets. Plus, be sure to join us for our pre-conference workshop that surveys novel tools and technologies for metabolic syndrome research. For up-to-date information on this event and to register, visit www.LifeSciencesInfo.com/metabolic.